Abstract
No clinical breakpoints are available to delineate antifungal drug efficacy in non-Aspergillus invasive mold infections (NAIMIs). In this analysis of 39 NAIMI episodes, the MIC of the first-line antifungal drug was the most important predictor of therapeutic response. For amphotericin B, an MIC of ≤0.5 μg/ml was significantly associated with better 6-week outcomes.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Amphotericin B / pharmacology
-
Amphotericin B / therapeutic use
-
Antifungal Agents / pharmacology*
-
Antifungal Agents / therapeutic use*
-
Child
-
Child, Preschool
-
Fungi / drug effects*
-
Humans
-
Invasive Fungal Infections / drug therapy*
-
Invasive Fungal Infections / microbiology*
-
Male
-
Microbial Sensitivity Tests
-
Middle Aged
-
Prognosis
-
Retrospective Studies
-
Treatment Outcome
-
Young Adult
Substances
-
Antifungal Agents
-
Amphotericin B
Grants and funding
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.